Partners

In addition to advancing our own pipeline, Mersana is accelerating the development of novel ADC therapies for patients in dire need of better treatments through strategic collaborations with leading pharmaceutical and biotech companies.

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522. Takeda obtains rights to Mersana’s XMT-1522 outside U.S. and Canada and the ability to create additional Fleximer ADCs.  Mersana receives $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment and an option to co-develop one of Takeda’s Fleximer ADCs in the US.

View Press Release

Mersana entered into a collaboration with Merck Serono in June 2014 to develop novel antibody drug conjugates against multiple undisclosed targets using our Fleximer platform and monoclonal antibodies provided by Merck Serono.

View Press Release

Mersana entered into an oncology-focused collaboration with Asana BioSciences, formerly part of Endo Pharmaceuticals, in March 2012 to develop novel antibody drug conjugates using our Fleximer platform and antibodies provided by Asana.

View Press Release